Skip to content

ARCH THERAPEUTICS, INC.: 10-Q filed 2015-05-07

What ARCH THERAPEUTICS, INC. reported in its quarterly report filed 2015-05-07 (fiscal Q2 2015): 21 published measures, 62 facts as tagged in accession 0001144204-15-028272.

This filing

Form
10-Q (quarterly report)
Filed
2015-05-07
Fiscal period
fiscal Q2 2015
Accession
0001144204-15-028272 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ARCH THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-03-31606,041USD
At 2014-09-30876,990USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-03-316,535,408USD
At 2014-09-307,769,433USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-03-31-5,929,367USD
At 2014-09-30-6,892,443USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-03-31573,600USD
At 2014-09-30833,520USD
At 2014-03-312,631,285USD
At 2013-09-30557,319USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-01-01 to 2015-03-31-833,966USD90
2014-10-01 to 2015-03-31-454,821USD182
2014-01-01 to 2014-03-31-8,380,156USD90
2013-10-01 to 2014-03-31-9,188,596USD182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2015-01-01 to 2015-03-310USD90
2014-10-01 to 2015-03-310USD182
2014-01-01 to 2014-03-310USD90
2013-10-01 to 2014-03-310USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-03-31-13,229,515USD
At 2014-09-30-12,774,694USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2015-01-01 to 2015-03-3176,076,487shares90
2014-10-01 to 2015-03-3174,716,734shares182
2014-01-01 to 2014-03-3167,344,404shares90
2013-10-01 to 2014-03-3163,744,820shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2015-01-01 to 2015-03-31-0.01USD/shares90
2014-10-01 to 2015-03-31-0.01USD/shares182
2014-01-01 to 2014-03-31-0.12USD/shares90
2013-10-01 to 2014-03-31-0.14USD/shares182

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-10-01 to 2015-03-31609,272USD182
2013-10-01 to 2014-03-31503,355USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-01-01 to 2015-03-31-1,255,672USD90
2014-10-01 to 2015-03-31-2,525,763USD182
2014-01-01 to 2014-03-31-1,295,573USD90
2013-10-01 to 2014-03-31-2,076,248USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-03-31606,041USD
At 2014-09-30876,990USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2015-01-01 to 2015-03-3150,556USD90
2014-10-01 to 2015-03-3178,320USD182
2014-01-01 to 2014-03-3127,765USD90
2013-10-01 to 2014-03-3155,530USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-03-311,392,163USD
At 2014-09-302,723,667USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2015-03-31204,099USD
At 2014-09-30175,832USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-01-01 to 2015-03-311,255,672USD90
2014-10-01 to 2015-03-312,525,763USD182
2014-01-01 to 2014-03-311,295,573USD90
2013-10-01 to 2014-03-312,076,248USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-01-01 to 2015-03-31402,495USD90
2014-10-01 to 2015-03-31802,230USD182
2014-01-01 to 2014-03-31487,090USD90
2013-10-01 to 2014-03-31630,756USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-03-3176,076,487shares
At 2014-09-3072,076,487shares

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2015-03-3132,441USD
At 2014-09-3043,470USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-01-01 to 2015-03-31853,177USD90
2014-10-01 to 2015-03-311,723,533USD182
2014-01-01 to 2014-03-31808,483USD90
2013-10-01 to 2014-03-311,445,492USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2014-10-01 to 2015-03-3128,267USD182
2013-10-01 to 2014-03-31-210,614USD182

Inspect the source

Entity
ARCH THERAPEUTICS, INC. / CIK 0001537561
Captured
SEC response SHA-256
63d0e84748ee59ab7c6817be68d0a32b23d83273213bc50081bb86253a1d4cc2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001537561.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))